A Prospective, Non-Intervention, Multi-Center Observational Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet in Patients With Erosive Gastroesophageal Reflux Disease
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Fexuprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 24 Jan 2025 Status changed from active, no longer recruiting to completed.
- 12 Jun 2024 Planned End Date changed from 30 Jun 2024 to 31 Dec 2024.
- 12 Jun 2024 Status changed from recruiting to active, no longer recruiting.